Company news
Alterity Therapeutics Ltd. news in 2022
Alterity Therapeutics Ltd.'s news releases, calls and decks from 2022, newest first.
New US patent for compounds to treat neurodegeneration
December 29, 2022
ATH434 Clinical Trial launched in Australia
October 13, 2022
US FDA Approval for IND Application for ATH434 for MSA
September 19, 2022
Appendix 4E & Annual Report 2022
August 31, 2022
ATH434 Phase 2 clinical launched in Europe
August 25, 2022
First Patient dosed in ATH434 Phase 2 Clinical Trial
July 6, 2022
Alterity receives a $4.1 million R&D Tax Refund
June 30, 2022
Regulatory Approval to Proceed with Phase 2 Trial in Italy
June 22, 2022
Alterity Launches ATH434 Phase 2 Clinical Trial
June 2, 2022
UK Regulatory Authorisation to Proceed with Phase 2 Trial
April 27, 2022
New publication shows ATH434 rescues neurons in MSA model
January 28, 2022
Response to ASX Query
January 12, 2022
New US Patent for Compounds to Treat Neurodegeneration
January 5, 2022
Decks in 2022
- Shareholder Meeting (November 2022)
Shareholder meeting · 31 slides · Nov 11, 2022
- Investor Presentation (March 2022)
Investor deck · 32 slides · Mar 7, 2022